BusinessUpdated 20 min ago
Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment

The approval makes Biocon's pertuzumab the first biosimilar to receive EC marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach
Continue reading on Business Standard
Read full story Hello Headlines links you to the original publisher for the full story.


